Log In
Print
BCIQ
Print
Print this Print this
 

ALX-0761

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionTrivalent bi-specific Nanobody against IL-17A and IL-17F
Molecular Target Interleukin-17A (IL-17A) ; Interleukin-17F (IL-17F)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe psoriasis
Regulatory Designation
Partner Merck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today